1.Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.
Xiaojun LIU ; Shuguang JIANG ; Chongyun FANG ; Hua LI ; Xuhua ZHANG ; Fuqin ZHANG ; Carl H JUNE ; Yangbing ZHAO
Protein & Cell 2017;8(7):514-526
The generation of T cells with maximal anti-tumor activities will significantly impact the field of T-cell-based adoptive immunotherapy. In this report, we found that OKT3/IL-2-stimulated T cells were phenotypically more heterogeneous, with enhanced anti-tumor activity in vitro and when locally administered in a solid tumor mouse model. To further improve the OKT3/IL-2-based T cell manufacturing procedure, we developed a novel T cell stimulation and expansion method in which peripheral blood mononuclear cells were electroporated with mRNA encoding a chimeric membrane protein consisting of a single-chain variable fragment against CD3 and the intracellular domains of CD28 and 4-1BB (OKT3-28BB). The expanded T cells were phenotypically and functionally similar to T cells expanded by OKT3/IL-2. Moreover, co-electroporation of CD86 and 4-1BBL could further change the phenotype and enhance the in vivo anti-tumor activity. Although T cells expanded by the co-electroporation of OKT3-28BB with CD86 and 4-1BBL showed an increased central memory phenotype, the T cells still maintained tumor lytic activities as potent as those of OKT3/IL-2 or OKT3-28BB-stimulated T cells. In different tumor mouse models, T cells expanded by OKT3-28BB RNA electroporation showed anti-tumor activities superior to those of OKT3/IL-2 T cells. Hence, T cells with both a less differentiated phenotype and potent tumor killing ability can be generated by RNA electroporation, and this T cell manufacturing procedure can be further optimized by simply co-delivering other splices of RNA, thus providing a simple and cost-effective method for generating high-quality T cells for adoptive immunotherapy.
Animals
;
CD28 Antigens
;
genetics
;
immunology
;
Electroporation
;
Humans
;
Immunity, Cellular
;
Interleukin-2
;
immunology
;
K562 Cells
;
Mice
;
Muromonab-CD3
;
immunology
;
Neoplasms, Experimental
;
genetics
;
immunology
;
pathology
;
RNA, Messenger
;
genetics
;
immunology
;
T-Lymphocytes
;
immunology
;
Tumor Necrosis Factor Receptor Superfamily, Member 9
;
genetics
;
immunology